Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wu, Y. L.
Right arrow Articles by Tariq, V. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, Y. L.
Right arrow Articles by Tariq, V. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1999) 44, 389-392
© 1999 The British Society for Antimicrobial Chemotherapy

Brief report

Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa

Ya Li Wua, Eileen M. Scotta,*, Alain Li Wan Pob and Vicki N. Tariqc

a School of Pharmacy and c School of Biology and Biochemistry, The Queen's University of Belfast, Medical Biology Centre, Belfast BT9 7BL b School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK

The ability of combinations of azlocillin and tobramycin to prevent or delay resistance development in eight Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients was studied using chequerboard titration and in-vitro serial subculture. No isolate had developed resistance to tobramycin after 12 treatments with the antibiotic combination. Azlocillin resistance had not developed in four isolates after 16 exposures, and was delayed in the other four isolates for at least eight exposures. ß-Lactamase production was responsible for azlocillin resistance in two isolates and occurred to a lesser extent in a third.

* Corresponding author. Tel: +44-1232-272027; Fax: +44-1232-247794; E-mail: e.scott{at}qub.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
M. Paul, I. Benuri-Silbiger, K. Soares-Weiser, and L. Leibovici
{beta} lactam monotherapy versus {beta} lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials
BMJ, March 20, 2004; 328(7441): 668.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
M. Paul, K. Soares-Weiser, and L. Leibovici
{beta} lactam monotherapy versus {beta} lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis
BMJ, May 22, 2003; 326(7399): 1111.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.